Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
Antonio Gallo, Rocco Capuano, Giovanna Donnarumma, Alvino Bisecco, Elena Grimaldi, Miriana Conte, Alessandro d’Ambrosio, Nicola Coppola, Massimiliano Galdiero, Gioacchino Tedeschi
Topics & Concepts
MedicineOcrelizumabImmunogenicityAntibody responseSpike ProteinImmunologyAntibodyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Multiple sclerosisReactogenicityVirologyInternal medicineDiseaseInfectious disease (medical specialty)RituximabSARS-CoV-2 and COVID-19 ResearchMultiple Sclerosis Research StudiesPeripheral Neuropathies and Disorders